Finally, cFLIP downregulation sensitized B lymphoma cells to TRAIL-induced apoptosis and breast cancer cells to ligand-independent but FADD-, caspase 8- and caspase 9-dependent apoptosis (65, 67), suggesting that HOIPIN-8, which downregulated cFLIP expression, could potentially be developed into therapeutics for B cell lymphoma as well as systemic lupus, particularly the disease caused by heightened apoptosis threshold due to lack of FAS. This evidence concerns the gene CASP9 and breast cancer.